Tag: pitts


Jury Says “Not Guilty” to Off-label Charges in Medical Device Case

March 3, 2016 – As the FDA fails to update or further clarify its policy regarding off-label promotion, the courts continue to hear cases that are being decided in favor of allowing.S. District Judge Royce Lamberth has entered an order dismissing the case; it is not subject to appeal. companies to share truthful and non-misleading […]

Read more

Industry More Than Ready for FDA Off-label Communications Guidance

Feb. 2, 2016 – The FDA’s recent announcement regarding which new and revised guidance documents it plans to publish in 2016 includes four long-awaited guidance documents by the Office of Prescription Drug Promotion (OPDP). “While the agency has been pondering its options, consumers and health professionals are expecting the industry to move forward and participate […]

Read more

Pitts Reminds Companies They Need To Be Careful With Sponsored Tweets

Sept. 9, 2013 – In a recent blog post on Drugwonks.com, entitled “Tweeter Reflux,” Peter Pitts reminded industry that although social media may pose complex questions, sponsored tweets are not that complicated. They are paid advertisements, pure and simple. Pitts cites AstraZeneca’s recent withdrawal of paid ads from the Associated Press’ Twitter feed because although […]

Read more

Pitts: Important Details on Government Detailing

June 13, 2012 – In a recent blog entry on Drugwonks.com, Center for Medicine in the Public Interest President and Co-founder Peter Pitts provides a link to his article on government detailing in a recent issue of the Drug Information Journal (). In the article, Pitts states that this so-called “academic” detailing is important to […]

Read more